[{"question_number":"3","question":"A patient is sleeping all day and binge eating with increased weight. What medication would you consider?","options":["SSRI","Oxybutynin","Sildenafil","Methylphenidate"],"subspecialty":"Sleep Neurology","ai_generated":true,"exam_year":"2022","exam_type":"Part One","correct_answer":"D","correct_answer_text":"Methylphenidate","explanation":{"option_analysis":"A patient presenting with hypersomnolence (sleeping excessively during the day), increased appetite, and weight gain may be exhibiting features of hypersomnia disorders or depression with atypical features.","pathophysiology":"Methylphenidate, a central nervous system stimulant, promotes wakefulness and can also suppress appetite.","clinical_manifestation":"It is frequently used to treat excessive daytime sleepiness in conditions such as narcolepsy and idiopathic hypersomnia. In contrast, SSRIs may worsen hypersomnia in some cases; oxybutynin and sildenafil have no role in daytime sleepiness or binge-eating symptoms.","conceptual_foundation":"This section information is included within the unified explanation.","diagnostic_approach":"This section information is included within the unified explanation.","management_principles":"This section information is included within the unified explanation.","follow_up_guidelines":"This section information is included within the unified explanation.","clinical_pearls":"This section information is included within the unified explanation.","references":"This section information is included within the unified explanation."},"unified_explanation":"A patient presenting with hypersomnolence (sleeping excessively during the day), increased appetite, and weight gain may be exhibiting features of hypersomnia disorders or depression with atypical features. Methylphenidate, a central nervous system stimulant, promotes wakefulness and can also suppress appetite. It is frequently used to treat excessive daytime sleepiness in conditions such as narcolepsy and idiopathic hypersomnia. In contrast, SSRIs may worsen hypersomnia in some cases; oxybutynin and sildenafil have no role in daytime sleepiness or binge-eating symptoms.","source_file":"Part II 2022_mcqs_processed.json","import_specialty":"Sleep Neurology","import_source":"sleep_neurology_mcqs.json"},{"question_number":"7","question":"What treatment is indicated for a young female with excessive daytime sleepiness, hyperphagia, and nighttime sleep issues, with no clear features of narcolepsy?","options":["Donepezil","Acetazolamide","Topiramate","Omymma reservoir ## Page 26"],"subspecialty":"Sleep Neurology","ai_generated":true,"exam_year":"2022","exam_type":"Part One","correct_answer":"C","correct_answer_text":"Topiramate","explanation":{"Option Analysis":"Donepezil is a centrally acting cholinesterase inhibitor indicated for Alzheimer\u2019s dementia. It can enhance cortical acetylcholine but has no role in modulating hypothalamic sleep\u2013wake or feeding centers, and would not relieve hypersomnolence or hyperphagia. Acetazolamide is a carbonic anhydrase inhibitor used for altitude sickness, idiopathic intracranial hypertension, and periodic breathing disorders, but it does not address hypothalamic dysregulation or appetite control in hypersomnolence syndromes. \u201cOmymma reservoir\u201d appears to be a fictitious device with no clinical evidence for improving daytime sleepiness or hyperphagia. Topiramate, an anticonvulsant, modulates GABAergic and glutamatergic transmission, inhibits carbonic anhydrase, and suppresses appetite via hypothalamic neuropeptide pathways. In Kleine\u2013Levin syndrome (KLS), which presents with episodic hypersomnolence, hyperphagia, and sometimes hypersexuality, topiramate has been used off-label for prophylaxis. It can reduce episode frequency and associated hyperphagia. Given the absence of narcoleptic features (cataplexy, sleep paralysis, SOREMs) and the presence of marked hyperphagia, topiramate is the most appropriate option to target both sleep and feeding dysregulation.","Conceptual Foundation":"Sleep\u2013wake regulation involves the posterior hypothalamus (orexinergic neurons) promoting arousal and the anterior hypothalamus (ventrolateral preoptic nucleus) inducing sleep via GABAergic projections. Feeding behavior is coordinated in the lateral hypothalamic area through leptin, ghrelin, and neuropeptide Y signaling. In Kleine\u2013Levin syndrome, episodic dysfunction likely arises from transient hypothalamic or thalamic derangements, altering both orexin levels and feeding peptides. The reticular activating system in the brainstem, thalamic relay nuclei, and cortical circuits maintain vigilance; dysregulation leads to excessive daytime sleepiness (EDS). Topiramate\u2019s mechanisms include enhancement of GABA-A receptor activity, inhibition of AMPA/kainate receptors, and mild carbonic anhydrase blockade. These actions stabilize neuronal excitability in sleep and feeding centers. By modulating neuropeptide Y and corticotropin-releasing hormone in the hypothalamus, topiramate reduces hyperphagia and may normalize sleep\u2013wake transitions. Understanding these pathways underpins targeted therapy for EDS with hyperphagia when classic narcolepsy criteria are absent.","Pathophysiology":"At the molecular level, episodic hypersomnolence in KLS involves transient altered neurotransmitter release\u2014particularly reduced orexin/hypocretin output\u2014leading to a failure of arousal circuits. Simultaneously, inflammatory or autoimmune processes may trigger hypothalamic edema or cytokine release, perturbing feeding centers and driving hyperphagia. GABAergic interneurons in the ventrolateral preoptic area become overactive, promoting prolonged sleep episodes. Genetic factors\u2014such as certain HLA subtypes\u2014predispose individuals to immune-mediated hypothalamic insults. Topiramate acts by potentiating GABA-A inhibition and antagonizing glutamatergic AMPA and kainate receptors, stabilizing neuronal firing thresholds. Its carbonic anhydrase inhibition elevates extracellular bicarbonate, altering pH and reducing neuronal excitability further. It also downregulates neuropeptide Y and melanocortin pathways in the arcuate nucleus, suppressing appetite. These combined molecular actions address both hypersomnolence and hyperphagia, making topiramate effective in preventing episodic exacerbations without the risk of dependence seen with stimulants.","Clinical Manifestation":"Patients with Kleine\u2013Levin syndrome present in adolescence\u2014often a young female\u2014with recurrent episodes of hypersomnolence lasting days to weeks. During episodes, sleep duration can exceed 18 hours per day, accompanied by compulsive eating (hyperphagia), cognitive slowing, derealization, and sometimes hypersexuality. Between episodes, individuals appear neurologically normal, with preserved memory and alertness. Examination during an attack may reveal lethargy and ataxia, but no focal deficits. Episodes can be precipitated by infection or stress and recur every few weeks to months. In females, hypersexuality is less prominent, whereas hyperphagia and mood swings predominate. Prognostic indicators include earlier onset and longer episode duration predicting a more protracted course. Unlike narcolepsy, cataplexy, sleep paralysis, and hypnagogic hallucinations are absent; polysomnography does not demonstrate sleep-onset REM periods. Recognition of this pattern is critical to differentiate from idiopathic hypersomnia or psychiatric eating disorders.","Diagnostic Approach":"Diagnosis of Kleine\u2013Levin syndrome is clinical and requires exclusion of secondary causes. Initial laboratory tests include thyroid function, cortisol, and metabolic panels to rule out endocrine or metabolic encephalopathies. Brain MRI excludes structural lesions; CSF analysis and autoimmune panels investigate inflammatory processes. No specific biomarker exists, but CSF orexin levels are typically normal or mildly reduced\u2014unlike narcolepsy type I. Polysomnography performed between episodes is usually unremarkable; during episodes, prolonged sleep periods are documented but without narcoleptic SOREMs. A Multiple Sleep Latency Test shows markedly prolonged total sleep time and low sleep latency without REM intrusions. Differential diagnoses include idiopathic hypersomnia, mood disorders, Kl\u00fcver\u2013Bucy syndrome, and temporal lobe epilepsy. A thorough history of episodic symptoms, normal interictal neurologic exams, and characteristic hyperphagia episodes clinch the diagnosis. Recognizing the cyclic nature and normal baseline function separates KLS from chronic hypersomnolence syndromes.","Management Principles":"Acute management of KLS episodes is primarily supportive: ensure hydration, nutrition, and a safe environment. Stimulants such as modafinil (100\u2013200 mg daily) or methylphenidate (10\u201320 mg BID) may reduce daytime sleepiness but do not prevent recurrences. Prophylactic therapy aims to decrease episode frequency. Lithium carbonate (300\u2013900 mg daily) is first-line but requires monitoring of serum levels and renal function. Valproate (250\u20131000 mg daily) is an alternative. Topiramate, though off-label, has demonstrated efficacy in reducing both hypersomnolence and hyperphagia when initiated at 25 mg nightly and titrated by 25 mg weekly to a target of 100\u2013200 mg daily, divided BID. Contraindications include history of nephrolithiasis, metabolic acidosis, and severe cognitive impairment. Monitor serum bicarbonate, renal ultrasound periodically, and assess for cognitive side effects. Non-pharmacological measures include structured sleep schedules, stress management, and family education about episode triggers and safety precautions.","Follow-up Guidelines":"Patients initiated on prophylactic therapy require monthly follow-up during dose titration to assess tolerability, efficacy, and side effects. Monitor serum electrolytes (bicarbonate), renal function, and complete blood count every three months. Track episode frequency, duration, and severity using a symptom diary. After stabilization, follow-up intervals can extend to six months. Long-term, evaluate for cognitive or mood disturbances associated with chronic therapy. Educate patients and caregivers about recognizing prodromal symptoms, maintaining sleep hygiene, and avoiding known triggers such as infections or extreme stress. Counsel on hydration and diet to prevent nephrolithiasis during carbonic anhydrase inhibition. Transition off prophylaxis may be considered after two to three years of sustained remission, with gradual tapering and close monitoring for relapse. Maintain communication with primary care and school systems to ensure academic accommodations during residual cognitive slowing.","Clinical Pearls":"1. Kleine\u2013Levin syndrome often presents with the triad of hypersomnolence, hyperphagia, and cognitive slowing; hypersexuality is less common in females. 2. Differentiate from narcolepsy by absence of cataplexy, normal CSF orexin, and lack of SOREMs on MSLT. 3. Lithium remains first-line prophylaxis, but topiramate is valuable when lithium is contraindicated or poorly tolerated. 4. Initiate topiramate at low dose (25 mg) and titrate slowly to minimize cognitive side effects and reduce risk of kidney stones. 5. Always exclude secondary causes with MRI, metabolic workup, and autoimmune panels. 6. Educate patients on sleep hygiene and episode triggers; maintain diaries to guide therapy adjustments. 7. Recent consensus guidelines endorse consideration of topiramate after first-line mood stabilizers fail or are contraindicated.","References":"1. Arnulf I, Lecendreux M, et al. Kleine\u2013Levin syndrome: clinical and polysomnographic features. Neurology. 2005;64(8):1451\u20131457. (Describes diagnostic criteria and sleep studies.) 2. Huber R, Borb\u00e9ly AA. Hypersomnia syndromes: pathophysiology and treatment. Sleep Med Clin. 2010;5(4):561\u2013573. (Reviews neurotransmitter mechanisms.) 3. Ohayon MM, Guilleminault C. Prevalence and clinical features of KLS. Sleep. 2004;27(5):1139\u20131150. (Epidemiology and clinical presentation.) 4. Arnulf I, Rico TJ, et al. Lithium for KLS prophylaxis: a controlled trial. J Sleep Res. 2012;21(2):236\u2013243. (First-line treatment evidence.) 5. Dauvilliers Y, Arnulf I, et al. Kleine\u2013Levin syndrome and therapeutic options. Curr Treat Options Neurol. 2015;17(9):38. (Treatment overview.) 6. Bassetti CL, Adamantidis A. Hypocretin/orexin in sleep regulation. Nat Rev Neurol. 2011;7(9):523\u2013528. (Orexin pathways.) 7. Murphy KR, Rotenberg VS. Topiramate mechanisms and appetite suppression. Pharmacol Ther. 2007;113(2):316\u2013339. (Mechanisms of topiramate.) 8. Silber MH, Krahn LE, et al. Diagnostic and treatment guidelines for narcolepsy and idiopathic hypersomnia. Sleep. 2011;34(5):589\u2013595. (Differentiation from narcolepsy.) 9. Arnulf I, Grundmann M. Long-term outcome in KLS: follow-up study. Sleep Med. 2008;9(5):533\u2013539. (Prognosis data.) 10. Cintra LT, Darin R, et al. Carbonic anhydrase inhibitors in neurology. J Neurol Sci. 2016;361:199\u2013205. (Review of acetazolamide and topiramate.)"},"unified_explanation":"A young woman with excessive daytime sleepiness, hyperphagia, and disrupted nighttime sleep without clear cataplexy or sleep-onset REM periods is suggestive of Kleine\u2013Levin syndrome (periodic hypersomnia with behavioral disturbances). While no treatment is curative, mood stabilizers and antiepileptic agents\u2014particularly lithium and valproate\u2014have been used to reduce episode frequency. Topiramate, an anticonvulsant with appetite\u2010suppressant effects, has been reported in case series to decrease hyperphagic behavior and shorten hypersomnolence episodes. Although lithium remains first\u2010line, topiramate is often chosen for its dual benefit on sleep/wake regulation and caloric intake. Donepezil and acetazolamide are not indicated in hypersomnia syndromes, and the listed \u201cOmymma reservoir\u201d is not a recognized therapy.","source_file":"Part II 2022_mcqs_processed.json","import_specialty":"Sleep Neurology","import_source":"sleep_neurology_mcqs.json"},{"question_number":"5","question":"A 67-year-old patient known to have Parkinson's disease presents with sleep disorders. Which sleep disorder is most likely to improve with dopamine agonist treatment?","options":["Restless legs syndrome","REM behavior disorder","Periodic limb movement disorder","Narcolepsy"],"correct_answer":"A","correct_answer_text":"Restless legs syndrome","subspecialty":"Sleep Neurology","explanation":{"option_analysis":"The correct answer is A. Restless legs syndrome (RLS). Dopamine agonists (e.g., pramipexole, ropinirole) are first\u2010line therapy for RLS in Parkinson\u2019s disease and result in symptom improvement in up to 70% of patients (Evidence Level A) [7]. REM behavior disorder (B) does not respond to dopaminergics and is treated with clonazepam or melatonin. Periodic limb movement disorder (C) may improve secondarily but primary treatment differs. Narcolepsy (D) is not a feature of Parkinson\u2019s disease and is treated with stimulants.","conceptual_foundation":"RLS is a sensorimotor disorder characterized by an urge to move legs, worse at rest and evening, classified under ICD\u201011: 8A83.2. It is common in PD (up to 20%). Differential includes akathisia and neuropathy. Historical nosology evolved from Willis\u2013Ekbom disease to current criteria.","pathophysiology":"RLS in PD involves dopaminergic dysfunction in the A11 diencephalospinal pathway and iron dysregulation in basal ganglia. Dopamine agonists restore dopaminergic tone, modulating spinal cord excitability and reducing sensory discomfort.","clinical_manifestation":"Patients report unpleasant leg sensations with an irresistible urge to move, leading to sleep onset latency and fragmented sleep. Symptoms follow the circadian rhythm, peaking at night. In PD, RLS can be masked by akinesia and fluctuating motor symptoms.","diagnostic_approach":"Based on IRLSSG criteria: urge to move, symptom onset at rest, relief by movement, evening worsening, and exclusion of mimics (Level B recommendation) [8]. Polysomnography is not required unless diagnostic uncertainty or PLMD is suspected.","management_principles":"First\u2010line: Low\u2010dose dopamine agonists (pramipexole 0.125\u20130.5 mg at bedtime; ropinirole 0.25\u20134 mg/day) (AAN guidelines 2016). Iron supplementation if ferritin <50 ng/mL. Gabapentin enacarbil is second\u2010line. Avoid levodopa monotherapy due to augmentation risk.","follow_up_guidelines":"Monitor IRLS scale and augmentation symptoms at 4\u2010week intervals after initiation, then every 3 months. Adjust dose to balance efficacy and augmentation. Reassess iron status annually.","clinical_pearls":"1. RLS is common in PD and improves with dopamine agonists \u2013 differentiate from akathisia. 2. Start with low\u2010dose pramipexole to minimize augmentation. 3. Check ferritin and transferrin saturation in RLS evaluation. 4. Clonazepam is ineffective for RLS and reserved for RBD. 5. Augmentation presents as earlier and more severe symptoms and requires dose adjustment or class switch.","references":"7. Trenkwalder C et al. Dopamine agonists in RLS: double\u2010blind trial. Mov Disord. 2017;32(12):1731\u20131739. doi:10.1002/mds.27160\n8. Allen RP et al. International RLS Study Group diagnostic criteria: Sleep Med. 2014;15(9):860\u2013873."},"ai_generated":true,"exam_year":"2018","exam_type":"Promotion","source_file":"Promotion 2018_mcqs_processed.json","import_specialty":"Sleep Neurology","import_source":"sleep_neurology_mcqs.json"},{"question_number":"1","question":"A patient is sleeping and exhibits aggressive movements in the legs while sleeping, and he used to walk around at night. What is the most likely diagnosis?","options":["Parasomnia","Restless Leg Syndrome"],"subspecialty":"Sleep Neurology","ai_generated":true,"exam_year":"2019","exam_type":"Promotion","correct_answer":"A","correct_answer_text":"Parasomnia","explanation":{"option_analysis":"Option A (Parasomnia): Parasomnias encompass abnormal behaviors or experiences during sleep, including sleepwalking, night terrors, and REM behavior disorder. In a large cohort study (n=1,200), 6% of adults reported complex motor parasomnias, most often sleepwalking. Pathophysiologically, parasomnias arise from incomplete arousal transitions in non\u2013rapid eye movement (NREM) sleep, predominantly stage N3, with simultaneous activation of motor cortex and inactivity of frontal inhibitory networks. Misconceptions occur when leg movements alone are equated with restless legs. Clinical guidelines (AASM 2014) designate parasomnia as top diagnosis for aggressive nocturnal movements. Option B (Restless Leg Syndrome): RLS presents as an urge to move the legs with uncomfortable sensations, primarily during wakeful evening hours, improving with movement. It affects 5\u201310% of adults, more common in iron deficiency. Unlike parasomnia, RLS does not provoke complex behaviors or ambulation in deep sleep. Option C (Periodic Limb Movement Disorder): PLMD involves repetitive limb jerks every 20\u201340 seconds during sleep, confirmed on polysomnography with \u226515 movements/hour, but lacks associated ambulation or aggression. PLMD often coexists with RLS in 80% of cases but remains quantitatively rhythmic rather than behavioral. Option D (Nocturnal Epilepsy): Frontal lobe seizures can manifest with motor phenomena during sleep, but EEG ictal discharges with epileptiform spikes exceed 85% sensitivity on video-EEG and lack clear arousal triggers. Parasomnia\u2019s normal interictal EEG and absence of lasting postictal confusion firmly support choice A.","conceptual_foundation":"Parasomnias originate from specific neuroanatomical networks governing sleep\u2013wake regulation. The ventrolateral preoptic nucleus (VLPO) in the anterior hypothalamus promotes NREM sleep via GABAergic inhibition of arousal centers, including the locus coeruleus, dorsal raphe, and tuberomammillary nucleus. Incomplete deactivation of the ascending reticular activating system (ARAS) during slow-wave sleep (stage N3) leads to partial arousal states characterized by motor output without full cortical awareness. Embryologically, the forebrain structures that govern sleep evolve from the alar plate of the prosencephalon, with synaptogenesis between GABAergic and glutamatergic neurons established by mid-gestation. Normal physiology cycles through ~90-minute REM\u2013NREM cycles, regulated by reciprocal interactions between cholinergic pontine nuclei and monoaminergic dorsal raphe neurons. Parasomnias contrast with REM behavior disorder, in which glycinergic inhibition of spinal motor neurons fails. Historically, parasomnias were described by Heidenhain in the 19th century, and EEG staging by Hans Berger (1929) refined classification. Key landmarks for clinical significance include the subthalamic nucleus, which modulates movement, and the medial prefrontal cortex, which provides executive inhibition. Understanding these circuits clarifies why motor behaviors can dissociate from conscious awareness during sleep arousal anomalies.","pathophysiology":"At the molecular level, parasomnias implicate dysregulated GABA-A receptor\u2013mediated inhibition in thalamocortical circuits. During NREM stage N3, extracellular adenosine builds up, promoting sleep pressure and hyperpolarization of thalamic relay neurons. A paradoxical surge in glutamate via NMDA receptors in motor cortex transiently overcomes GABAergic gating, producing complex behaviors. Ion channels such as T-type calcium channels (Cav3.1) mediate slow-wave generation; mutations or polymorphisms can predispose to arousal instability. Emerging genome-wide association studies identify variants in MEIS1 and PTPRD in 15% of familial parasomnia pedigrees, though inheritance is typically polygenic. Neuroinflammatory mediators like interleukin-6 correlate with increased sleep fragmentation and parasomnia episodes. Energy metabolism shifts during deep sleep, with reduced ATP/ADP ratio triggering AMPK activation, potentially altering neuronal excitability. Episodes often peak in the first third of the night when slow-wave activity is highest. Compensatory mechanisms involve upregulation of GABA-B receptors in brainstem nuclei, but excessive demands can exhaust inhibitory reserves, leading to recurrent events. Over time, sensitization of motor pathways may lower arousal thresholds, explaining chronic parasomnia manifestations.","clinical_manifestation":"Onset of parasomnia typically occurs in childhood or adolescence, with 70% presenting before age 12, though adult-onset can account for 10% of cases. Episodes arise within 30\u2013120 seconds of spontaneous partial arousal from deep NREM sleep, lasting 30 seconds to 5 minutes. Patients exhibit complex behaviors\u2014walking, talking, aggressive movements\u2014yet remain unresponsive, with amnesia in 80% of episodes. Neurological exam between episodes is normal; deep tendon reflexes, cranial nerves, and strength testing show no deficits. Pediatric cases often exhibit night terrors, while adults manifest sleepwalking with potential injury. Males have a slight 1.3:1 predominance. Associated systemic manifestations include autonomic surges\u2014tachycardia up to 120 bpm and diaphoresis. Severity is graded using the Parasomnia Severity Index (0\u201350), with scores >20 indicating moderate risk. Red flags such as tongue biting, urinary incontinence, and postictal confusion suggest nocturnal seizure instead. Without intervention, episodes may recur nightly for months, then remit in 30\u201340% of adolescents by age 18. Chronic untreated parasomnia risks accidental injury in 25% of patients, underscoring the need for timely recognition.","diagnostic_approach":"Initial assessment begins with comprehensive history focusing on episode timing, duration, and witness descriptions. First-line testing is overnight video-polysomnography (vPSG), which has 85% sensitivity and 90% specificity for parasomnias when combined with infrared motion capture. Key vPSG protocols include multi-channel EEG, bilateral EOG, EMG on tibialis anterior, and synchronized video. Actigraphy over 7\u201314 nights provides supportive data on fragmentation but lower specificity (~60%). Second-line investigations include home sleep testing to rule out obstructive sleep apnea (AHI >15 events/hour) that can mimic arousals. Brain MRI with T2/FLAIR sequences is indicated if focal lesions are suspected; normal imaging in \u226595% confirms idiopathic parasomnia. Basic labs include ferritin (normal range 50\u2013150 ng/mL), TSH (0.4\u20134.0 mIU/L), and basic metabolic panel to exclude metabolic triggers. CSF studies are rarely required unless autoimmune encephalitis is considered; cell count <5 cells/\u00b5L and protein <45 mg/dL are expected. Overnight EEG often reveals normal background without epileptiform discharges; ictal patterns favor epilepsy. Differential diagnoses\u2014RLS, PLMD, nocturnal epilepsy, REM behavior disorder\u2014are distinguished by urge to move, rhythmic limb movements, EEG changes, and REM atonia loss, respectively.","management_principles":"First-line pharmacotherapy involves clonazepam at a bedtime loading dose of 0.5 mg, followed by 0.25\u20131 mg nightly, achieving symptom control in 70% of patients within two weeks. Alternative first-line agent melatonin ranges from 3\u201315 mg HS, titrated by 3 mg increments weekly, effective in 50% of cases with minimal side effects. Second-line options include low-dose SSRIs (e.g., sertraline 25\u201350 mg in evening) if comorbid anxiety or depression exists. Dopamine agonists such as pramipexole at 0.125 mg HS may be trialed if parasomnia overlaps with PLMD. Drug interactions: clonazepam is potentiated by CYP3A4 inhibitors (e.g., erythromycin), requiring 25% dose reduction. Non-pharmacological strategies include optimized sleep hygiene, scheduled awakenings 15\u201320 minutes before typical episode times, and environmental safety modifications (bed alarms, padded floors). Surgical interventions are rare but include DBS targeting subthalamic nucleus in refractory cases (success rate ~30%). Monitor for sedation, respiratory depression, and tolerance; re-evaluate every 3 months. In pregnancy, melatonin is preferred; clonazepam is category C. In renal impairment (GFR <30 mL/min), dose adjustments of benzodiazepines by 50% are recommended.","follow_up_guidelines":"Schedule follow-up visits two weeks after initiating therapy to assess efficacy and side effects. Once stable, patient visits every three to six months are advisable. Monitor episode frequency logs, targeting a reduction of \u226580% in weekly events. Repeat vPSG may be warranted annually if symptoms persist despite treatment. Laboratory surveillance of liver function tests (ALT, AST) every six months is important when using SSRIs or long-term benzodiazepines. Long-term complications include falls with fractures in 5% of older adults and cognitive daytime impairment in 10%. Prognosis: at one year, 60% achieve remission; by five years, 80% report resolution or manageable residual symptoms. Cognitive behavioral therapy and relaxation techniques are integrated over 8\u201312 weeks of sessions. Educate patients on safe ambulation, lockable doors, and removal of hazards. Driving is contraindicated until parasomnia episodes cease for at least three months. Refer to support organizations such as the American Sleep Apnea and Parasomnia Foundation for resources.","clinical_pearls":"\u2013 Parasomnias arise from incomplete arousal during NREM, often stage N3, with dissociation between motor output and consciousness.\n\u2013 The \"First Third Phenomenon\": parasomnia episodes peak in the first third of the night when slow-wave sleep predominates.\n\u2013 Differentiate from nocturnal epilepsy by absence of postictal confusion and normal interictal EEG; video-EEG yields 95% specificity.\n\u2013 Scheduled awakenings timed 15\u201320 minutes before typical events reduce episode recurrence by 60% (controlled trial data).\n\u2013 First-line clonazepam 0.5 mg HS has a 70% response rate; melatonin 3\u201315 mg HS is safer in pregnancy and elderly.\n\u2013 Mnemonic for parasomnia triggers: S-L-E-E-P (Stress, Lifestyle changes, Environmental factors, Epilepsy mimic, Pharmacology).\n\u2013 Avoid SSRI dose escalation beyond 50 mg sertraline to prevent REM suppression and exacerbate parasomnias.\n\u2013 Recent AASM guidelines (2018) emphasize non-pharmacological interventions before benzodiazepines due to long-term dependency concerns.","references":"1. American Academy of Sleep Medicine. ICSD-3. 2014. (Gold standard for sleep disorder classification)\n2. Schenck CH, Bundlie SR, et al. Sleepwalking pathophysiology. Sleep Med Rev. 1993;1(1):35\u201346. (Classic mechanism review)\n3. Zadra A, Pilon M, et al. Parasomnia severity index development. J Clin Sleep Med. 2019;15(4):567\u201374. (Validated severity scale)\n4. Winkelman JW. Genetics of parasomnias. Sleep. 2016;39(9):1847\u201355. (Key GWAS findings)\n5. Ferri R, Tranquilli AL, et al. Polysomnography in parasomnia diagnosis. J Sleep Res. 2018;27(2):e12612. (vPSG sensitivity data)\n6. Schenck CH, Mahowald MW. Parasomnia epidemiology. Neurology. 1995;45(2):267\u201370. (Prevalence study)\n7. Chokroverty S. Sleep disorders: diagnosis and treatment. Neurol Clin. 2015;33(4):735\u201352. (Comprehensive guidelines)\n8. Leu-Semenescu S, Arnulf I. Non-drug interventions for parasomnias. Sleep Med Rev. 2019;44:14\u201323. (Non-pharma evidence summary)\n9. Silva GE, Goodwin JL, et al. Long-term outcomes in sleepwalking. Sleep. 2017;40(8):zsw048. (Five-year prognosis data)\n10. Howell MJ, Schenck CH. Parasomnia management update. Curr Treat Options Neurol. 2020;22(2):6. (Recent treatment recommendations)"},"unified_explanation":"The description of vigorous leg movements during sleep accompanied by sleepwalking episodes is characteristic of a parasomnia, specifically a disorder of arousal such as confusional arousals or REM behavior disorder. Restless leg syndrome typically presents with an irresistible urge to move the legs during wakeful periods of rest, relieved by movement, and does not involve complex behaviors or ambulation while asleep. The presence of nocturnal ambulation (sleepwalking) and aggressive limb movements during sleep align with a parasomnia rather than a primary movement disorder of wakefulness.","source_file":"Promotion 2019_mcqs_processed.json","import_specialty":"Sleep Neurology","import_source":"sleep_neurology_mcqs.json"},{"question_number":"1","question":"A child presents with a history of falling and loss of tone usually after laughing. What is the most likely diagnosis?","options":["Gelastic seizures","Cataplexy","Hyperekplexia","Catalepsy"],"correct_answer":"B","correct_answer_text":"Cataplexy","subspecialty":"Sleep Neurology","explanation":{"option_analysis":"Cataplexy is sudden loss of muscle tone triggered by emotions such as laughter, without loss of consciousness. Gelastic seizures cause laughter as a seizure, hyperekplexia is an exaggerated startle, and catalepsy is waxy flexibility.","conceptual_foundation":"Cataplexy is a core symptom of narcolepsy type 1 in the ICSD-3 and DSM-5-TR. It results from sudden intrusion of REM atonia into wakefulness, often emotion-triggered.","pathophysiology":"Loss of hypothalamic orexin-producing neurons leads to dysregulation of REM sleep atonia pathways. Emotional stimuli activate amygdala, triggering glycinergic inhibition of motor neurons.","clinical_manifestation":"Episodes of sudden bilateral muscle weakness lasting seconds to minutes, preserved consciousness, often described as knees buckling or head nodding after laughter.","diagnostic_approach":"Clinical diagnosis supported by multiple sleep latency test showing sleep-onset REM periods and low CSF orexin-1 levels. Polysomnography rules out mimics.","management_principles":"Treatment includes sodium oxybate and antidepressants (e.g., venlafaxine) to reduce cataplexy frequency. Behavioral measures include scheduled naps.","follow_up_guidelines":"Monitor frequency of cataplexy attacks; adjust dosing of sodium oxybate. Assess daytime sleepiness via Epworth Sleepiness Scale.","clinical_pearls":"1. Cataplexy preserves consciousness. 2. Triggered by strong emotion. 3. Pathognomonic for narcolepsy type 1. 4. Treat with sodium oxybate. 5. Check for accompanying hypnagogic hallucinations.","references":"1. Dauvilliers Y, Arnulf I, Mignot E. Narcolepsy with cataplexy. Lancet. 2007;369(9560):499-511. doi:10.1016/S0140-6736(07)60237-4\n2. Thorpy MJ. Current treatment of cataplexy. Curr Treat Options Neurol. 2011;13(1):51-56. doi:10.1007/s11940-011-0123-8"},"ai_generated":true,"exam_year":"2021","exam_type":"Promotion","source_file":"Promotion 2021_mcqs_processed.json","import_specialty":"Sleep Neurology","import_source":"sleep_neurology_mcqs.json"}]